Analyst consensus puts Sun Pharma stock at INR 2,180.00
Published on 10/15/2026 at 15:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and stock valuation
- Analyst consensus sets a median Sun Pharma target of INR 2,180.00 on October 15, 2026.
- Fiscal 2026 sales reached INR 584.60 billion.
- Sun Pharma stock costs INR 1,764.00 on October 15, 2026, up 1.01 percent on the NSE versus the previous close of INR 1,746.40.
- Sun Pharma traded at a P/E ratio of 34.99 and a market capitalization of INR 4.2 trillion on October 15, 2026.
Analyst consensus places a median target of INR 2,180.00 on Sun Pharma stock, 23.58 percent above the INR 1,764.00 NSE price on October 15, 2026. Sharpely says 31 analysts cover the company, with 27 holding Buy or Strong Buy ratings.
Fiscal 2026 sales set the base
Sun Pharmaceutical Industries reported fiscal 2026 sales of INR 584.60 billion, up from INR 524.40 billion in fiscal 2025, according to Sharpely. The comparison implies 11.48 percent year-over-year growth and gives the current valuation a concrete earnings backdrop.
Price position remains measurable
The NSE price of INR 1,764.00 was up INR 17.60, or 1.01 percent, on October 15, 2026. The session range ran from INR 1,734.10 to INR 1,778.00, while volume reached 1,376,054 shares against an average of 1,835,488.
Sun Pharma stood 13.83 percent below its 52-week high of INR 2,046.90 and 11.38 percent above its 52-week low of INR 1,583.70. The stock's 52-week span therefore remains wide, with the current price closer to the lower half than to the peak.
Valuation and upcoming dates
The company carried a market capitalization of INR 4.2 trillion and a P/E ratio of 34.99 on October 15, 2026. Dr. Reddy's Laboratories traded at a P/E ratio of 30.69 and Cipla at 31.85 on the same date, placing Sun Pharma above both peers on this measure.
The postal-ballot voting period closes on October 31, 2026, and the results are due on or before November 3, 2026, according to Sun Pharmaceutical Industries.
Comparison with peers
Sun Pharma (NSE, INR): plus 1.01 percent, P/E 34.99, market capitalization INR 4.2 trillion
Dr. Reddy's Laboratories (NSE, INR): plus 0.23 percent, P/E 30.69, market capitalization INR 1.0 trillion
Cipla (NSE, INR): plus 1.02 percent, P/E 31.85, market capitalization INR 1.1 trillion
Trading level and valuation
Sun Pharma's INR 2,180.00 median analyst target stands 23.58 percent above the NSE price, while its P/E ratio is higher than the two peer figures listed above. The combination leaves the target distance and the upcoming postal-ballot dates as the clearest reference points for the stock.
Company: Sun Pharmaceutical Industries Limited
ISIN: INE044A01036
Ticker: SUNPHARMA
Primary exchange: NSE
Price NSE (as of October 15, 2026, 3:29 p.m. IST): INR 1,764.00
Change versus previous NSE close: plus 1.01 percent
Previous NSE close: INR 1,746.40
Market capitalization: INR 4.2 trillion (as of October 15, 2026)
52-week range: INR 1,583.70-INR 2,046.90 (as of October 15, 2026)
Sector / Industry: Healthcare / Pharmaceuticals
Market context: Market report BSE Sensex.
